Nov 18, 2019: Novartis Phase III PARAGON-HF study plays a key role for patients with diastolic heart failure with preserved ejection fraction (HFpEF).
From the analysis, it was found that, as compared to valsartan, treatment with Entresto may result in substantial reductions in heart failure hospitalizations and cardiovascular death. Women with HFpEF or recently hospitalized for heart failure determine additional benefits.
In addition, in a collective analysis of PARAGON-HF (HFpEF) and PARADIGM-HF (heart failure with reduced ejection fraction (HFrEF)), better treatment assistance was observed in patients with left ventricular ejection fraction (LVEF) below approximately 60%.
https://www.novartis.com/news/media-releases/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref
